Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. J of Skin. 2023;7(6):s291. doi:10.25251/skin.7.supp.291